Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
Status:
Not yet recruiting
Trial end date:
2027-07-15
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to compare treatment outcomes between an oral medication
(beta agonist) versus onabotulinumtoxinA injections in women with urgency urinary
incontinence (UUI).
Participants will be randomly selected to receive one of the two treatments. The primary
outcome measure will be at 3 months, and women will be followed for a total of 12 months.
Based on patient expert input, there are 2 primary outcomes: Treatment satisfaction and
urinary symptom severity.
Phase:
Phase 4
Details
Lead Sponsor:
Women and Infants Hospital of Rhode Island
Collaborators:
Brown University Howard University Patient-Centered Outcomes Research Institute University of Alabama at Birmingham University of California, San Diego University of New Mexico
Treatments:
abobotulinumtoxinA Adrenergic Agents Adrenergic Agonists Adrenergic beta-3 Receptor Agonists Botulinum Toxins, Type A